Skip to main content
See every side of every news story
Published • loading... • Updated

FDA Approves First Daily Pill for Weight Loss Treatment

The FDA approved the first daily oral GLP-1 drug for weight management, showing about 16.6% average weight loss in trials, expanding options beyond injections.

  • On Dec. 22, 2025 the U.S. Food and Drug Administration approved a pill version of Wegovy, Novo Nordisk A/S's first oral GLP-1 therapy cleared for weight management in the United States.
  • In the 64-week OASIS 4 trial, 307 adult participants randomized to oral semaglutide 25 mg showed mean weight loss of about 17% when treatment was adhered to.
  • Among trial participants, 76% achieved at least 5% weight loss; a 1.5 mg starting dose will be available in early January for $149 per month, and production is underway at Novo Nordisk North Carolina manufacturing sites.
  • Novo Nordisk plans a U.S. launch in early January 2026, including an indication to reduce major adverse cardiovascular events, while pricing and demand remain key market factors.
  • Facing competition from Eli Lilly, Novo Nordisk struggles to regain share as more patients choose Zepbound, while it argues a convenient GLP-1 pill without cold storage could boost interest but unclear if market share will rise.
Insights by Ground AI
Podcasts & Opinions

381 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 65% of the sources are Center
65% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Telemundo Area de la Bahía 48 broke the news on Monday, December 22, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal